Physician profile
Philip A Cole
NPI 1225249105
$2,338.97
in general payments reported to CMS, 2019-2025
15 companies · $41.18 in 2025
The $41.18 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $186 · 2021: $69.44 · 2022: $96.44 · 2023: $72.05 · 2024: $192 · 2025: $41.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,437.65 | 2019 | |
| Ethicon US, LLC | $337.99 | 2019-2025 | Dermabond Prineo, Enseal X1, Echelon; Endopath |
| Becton, Dickinson and Company | $113.33 | 2024 | Phasix Mesh |
| Organogenesis INC. | $100.30 | 2019 | |
| Braintree Laboratories, INC. | $80.57 | 2019-2020 | |
| Allergan, INC. | $69.99 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $35.50 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.17 | 2019 | |
| Smith+Nephew, INC. | $26.28 | 2019-2022 | |
| Baxter Healthcare | $25.72 | 2020 | |
| Solventum Corporation | $18.13 | 2024 | V.A.C. Veraflo |
| Kerecis Limited | $18.01 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Leica Microsystems INC. | $14.74 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.58 | 2019 | |
| Abbvie INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.